Immatics NV
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapie… Read more
Immatics NV (IMTX) - Total Assets
Latest total assets as of December 2025: $562.10 Million USD
Based on the latest financial reports, Immatics NV (IMTX) holds total assets worth $562.10 Million USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Immatics NV - Total Assets Trend (2018–2025)
This chart illustrates how Immatics NV’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Immatics NV - Asset Composition Analysis
Current Asset Composition (December 2025)
Immatics NV's total assets of $562.10 Million consist of 89.6% current assets and 10.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 61.5% |
| Accounts Receivable | $6.88 Million | 1.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.58 Million | 0.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Immatics NV's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Immatics NV's current assets represent 89.6% of total assets in 2025, a decrease from 90.2% in 2018.
- Cash Position: Cash and equivalents constituted 61.5% of total assets in 2025, down from 64.2% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 1.2% of total assets.
Immatics NV Competitors by Total Assets
Key competitors of Immatics NV based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Immatics NV - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Immatics NV generates 0.08x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Immatics NV is currently not profitable relative to its asset base.
Immatics NV - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.72 | 9.26 | 3.26 |
| Quick Ratio | 11.72 | 9.26 | 3.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $460.80 Million | $ 561.57 Million | $ 153.99 Million |
Immatics NV - Advanced Valuation Insights
This section examines the relationship between Immatics NV's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.78 |
| Latest Market Cap to Assets Ratio | 1.14 |
| Asset Growth Rate (YoY) | -19.3% |
| Total Assets | $562.10 Million |
| Market Capitalization | $639.97 Million USD |
Valuation Analysis
Above Book Valuation: The market values Immatics NV's assets above their book value (1.14 x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Immatics NV's assets decreased by 19.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Immatics NV (2018–2025)
The table below shows the annual total assets of Immatics NV from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $562.10 Million | -19.26% |
| 2024-12-31 | $696.15 Million | +36.51% |
| 2023-12-31 | $509.96 Million | +25.05% |
| 2022-12-31 | $407.82 Million | +133.51% |
| 2021-12-31 | $174.65 Million | -31.42% |
| 2020-12-31 | $254.65 Million | +89.64% |
| 2019-12-31 | $134.28 Million | +118.98% |
| 2018-12-31 | $61.32 Million | -- |